Ablynx NV (XBRU:ABLXS) Debt-to-Asset : 0.23 (As of Dec. 2017)

View and export this data going back to . Start your Free Trial

What is Ablynx NV Debt-to-Asset?

Ablynx NV's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2017 was €0.00 Mil. Ablynx NV's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2017 was €88.72 Mil. Ablynx NV's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Dec. 2017 was €389.85 Mil. Ablynx NV's debt to asset for the quarter that ended in Dec. 2017 was 0.23.

Ablynx NV Debt-to-Asset Historical Data

The historical data trend for Ablynx NV's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ablynx NV Debt-to-Asset Chart

Ablynx NV Annual Data

Trend

Dec08

Dec09

Dec10

Dec11

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

Debt-to-Asset

Get a 7-Day Free Trial

0.30

0.32

0.23

Ablynx NV Semi-Annual Data
	Dec07	Dec08	Jun09	Dec09	Jun10	Dec10	Jun11	Dec11	Jun12	Dec12	Jun13	Dec13	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17
Debt-to-Asset	Get a 7-Day Free Trial															0.30	0.26	0.32	-	0.23

Competitive Comparison of Ablynx NV's Debt-to-Asset

For the Biotechnology subindustry, Ablynx NV's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Ablynx NV's Debt-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Ablynx NV's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Ablynx NV's Debt-to-Asset falls into.

Ablynx NV Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Ablynx NV's Debt-to-Asset for the fiscal year that ended in Dec. 2017 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(0	+	88.715)	/	389.848
	=	0.23

Ablynx NV's Debt-to-Asset for the quarter that ended in Dec. 2017 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(0	+	88.715)	/	389.848
	=	0.23

Ablynx NV (XBRU:ABLXS) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

Ablynx NV Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of Ablynx NV's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Ablynx NV (XBRU:ABLXS) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ablynx NV (XBRU:ABLXS) » Definitions » Debt-to-Asset

Comparable Companies

Traded in Other Exchanges

N/A

Address

Website

http://www.ablynx.com

Ablynx NV is a biopharmaceutical company engaged in the development of Nanobodies, proprietary therapeutic proteins based on single-domain antibody fragments. It has 45 proprietary and partnered programs in development in various therapeutic areas including inflammation, hematology, immuno-oncology, oncology and respiratory disease. It has collaborations with multiple pharmaceutical companies including AbbVie; Boehringer Ingelheim; Eddingpharm; Merck & Co., Inc., Kenilworth, New Jersey, USA; Merck KGaA; Novartis; Novo Nordisk; Sanofi and Taisho Pharmaceuticals. The company generates revenue from research collaboration agreements and from government grants.

Ablynx NV (XBRU:ABLXS) Headlines

No Headlines